MONTREAL - Paladin Labs Inc., a subsidiary of Endo International plc (OTC: OTC:ENDPQ), has announced the availability of XCOPRI® (cenobamate tablets) for Canadian patients as an adjunctive treatment for partial-onset seizures in adults with epilepsy. This new medication option is for those who have not found adequate control with conventional therapy.
XCOPRI, which is taken orally once daily, functions through a dual mechanism of action, aiming to reduce repetitive neuronal firing and modulate the GABAA ion channel. Its efficacy and safety were evaluated in two placebo-controlled, double-blind clinical trials, where it demonstrated a significant reduction in seizure frequency and an increased responder rate compared to placebo.
The drug has received recommendations for public reimbursement from Canadian health agencies and is marketed in the U.S. and Europe under different trademarks. Paladin Labs is working with government payers to ensure access to XCOPRI for eligible patients.
Epilepsy affects roughly 300,000 Canadians, with 60% experiencing focal seizures. Despite available treatments, approximately 30% of patients continue to have seizures. XCOPRI's introduction provides a new therapeutic option for this patient population.
Endo International, Paladin Labs' parent company, is currently undergoing restructuring activities and has made forward-looking statements regarding product efficacy and availability. However, actual results and performance may differ due to various factors, including ongoing legal and financial restructuring processes.
This news article is based on a press release statement from Paladin Labs and Endo International plc.
InvestingPro Insights
As Paladin Labs introduces XCOPRI® to the Canadian market, investors and stakeholders in Endo International plc may be keen on understanding the company's financial health and market performance. According to real-time data from InvestingPro, Endo International has a market capitalization of a mere 0.14M USD, reflecting its current financial challenges. The company's revenue over the last twelve months as of Q3 2023 stood at 2069.6M USD, with a gross profit margin of 54.14%, indicating a relatively strong profitability on its sales. However, the revenue growth during this period has contracted by 18.92%, signaling potential headwinds in the company's operations.
InvestingPro Tips highlight that Endo International's stock has experienced significant price volatility, with a staggering 200% return over the last week, yet a dramatic 99.76% decline over the past year. This volatility could be a reflection of the market's reaction to both the restructuring activities of the company and the launch of new products like XCOPRI®. Analysts have revised their earnings downwards for the upcoming period, which could be a concern for potential investors. On a more positive note, the company's liquid assets exceed its short-term obligations, providing some financial flexibility in the near term.
For those considering an investment in Endo International, it's worth noting that the company is currently trading at a high EBITDA valuation multiple, which might be of interest to value investors. Additionally, there are more insights available; InvestingPro includes a range of additional tips for a more comprehensive analysis. To access these insights and strengthen your investment strategy, consider taking advantage of the special New Year sale for an InvestingPro subscription, now with a discount of up to 50%. Use coupon code SFY24 to get an additional 10% off a 2-year InvestingPro+ subscription, or SFY241 to get an additional 10% off a 1-year InvestingPro+ subscription.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.